Nicholas Jacobus

Currax Pharmaceuticals expands its impactful campaigns, showcasing real patient stories to empower those battling obesity and food cravings across the U.S.

Celltrion's Avtozma IV gains FDA approval for treating cytokine release syndrome, enhancing treatment options for patients aged 2 and older.

Explore how Wounded Warrior Project and advocates like Morgan Fox promote mental health awareness and support for veterans facing PTSD and depression.

The choice reflects the company's aims to revolutionize chronic care and expand global health solutions through innovative technology.

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia and expanding its cardiometabolic portfolio.

LENZ Therapeutics celebrates FDA approval of Vizz, the first aceclidine eye drop for presbyopia.

FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 diabetes patients.

Viridian Therapeutics partners with Kissei Pharmaceutical to advance treatments for thyroid eye disease in Japan, enhancing patient care and market potential.

Aetna enhances user experience with AI-driven Care Paths, simplifying health navigation and personalizing care for members and providers alike.

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination therapies for better patient outcomes.

The survey reveals how financial anxiety has become an everyday occurrence affecting everyday health through stress, relationship strain, and lack of sleep.

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

Current Novo Nordisk executive vice president of internal operations is named new president and CEO.

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth opportunities.

The segment will provide education and support strategies.

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene editing treatments for high-risk patients.

Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for patients and research breakthroughs.

The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare payment system.

Study presents overwhelming public support for providing aid to mothers in need.

The acquisition will bring Vicebo's Molecular Clamp technology under Sanofi's umbrella.

Regulators failed to halt production and importation of illegal GLP-1 compounds.

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS sciences.

Amphix Bio leads breakthrough of regenerative spinal cord injury treatment.

The building will provide biotech startups necessary tools and space to conduct research and development.

Waterdrop’s advancements in AI technology earned the company a place in the collection.

Studies presented at the Society of Neurointerventional Surgery’s show links between GLP-1s and the prevention of strokes and reductions in brain injury complications.

The deep learning model increases handheld 3D medical imaging access.

The SVP of educational development’s contribution to the book displays SKNV’s approach to furthering education and professional development.